< Back to search
Filter
1

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

for
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency),
Location: New Haven CT, New York NY, Houston TX, Sacramento CA
Sponsor: Duke Street Bio Ltd

Sex: All

Age: 18+

Code: NCT06458712

Phase1, Recruiting

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

for
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma,
Location: Bath ME, Portland ME, Scarborough ME, South Portland ME,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06958328

Phase3, Recruiting

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

for
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: All

Age: 18+

Code: NCT06984562

Recruiting

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Boston MA, New Haven CT, East Brunswick NJ,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07621718

Phase3, Recruiting

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 18+

Code: NCT07030283

Phase1, Recruiting

Interested in new adenocarcinoma, pancreatic ductal trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

for
Pancreatic Ductal Adenocarcinoma
Location: Bay Shore NY, New Hyde Park NY, Mount Kisco NY,
Sponsor: Northwell Health

Sex: All

Age: 18+

Code: NCT07163273

Phase2, Recruiting

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

for
Pancreatic Cancer, Pancreatic Neoplasms,
Location: Tampa FL
Sponsor: ARTIDIS AG

Sex: All

Age: 18+

Code: NCT07542041

Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

for
Non-small Cell Lung Cancer, Colorectal Carcinoma,
Location: Boston MA, New York NY, Philadelphia PA, Pittsburgh PA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06218914

Phase1, Recruiting

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

for
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute

Sex: All

Age: 18+

Code: NCT06821997

Phase2, Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC,
Location: Boston MA, New York NY, Washington D.C. DC, Fairfax VA,
Sponsor: Tango Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06922591

Phase1, Phase2, Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer,
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Verastem, Inc.

Sex: All

Age: 18+

Code: NCT07020221

Phase1, Phase2, Recruiting

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

for
Metastatic Pancreatic Ductal Adenocarcinoma
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT06904378

Phase1, Phase2, Recruiting

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

for
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Fairfax VA, Grand Rapids MI, Irving TX
Sponsor: Avacta Life Sciences Ltd

Sex: All

Age: 18+

Code: NCT07454642

Phase1, Recruiting

UCSF PANC Cyst Registry

for
Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Cancer,
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 18+

Code: NCT04291651

Recruiting

Durvalumab and Oleclumab in Resectable PDAC

for
Pancreatic Ductal Adenocarcinoma
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06060405

Phase2, Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

for
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma,
Location: New Haven CT, New York NY, Rochester NY, Detroit MI,
Sponsor: Panbela Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05254171

Phase2, Phase3, Recruiting

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

for
Gastric or Gastroesophageal Junction Adenocarcinoma,
Location: Fairfax VA, Durham NC, Pittsburgh PA, Louisville KY,
Sponsor: Phanes Therapeutics

Sex: All

Age: 18+

Code: NCT05482893

Phase1, Phase2, Recruiting

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

for
Advanced Pancreatic Adenocarcinoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT06454383

Phase1, Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer,
Location: Boston MA, New York NY, Fairfax VA, Pittsburgh PA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06128551

Phase1, Phase2, Recruiting

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

for
Solid Tumor, Adult, Colorectal Cancer,
Location: Houston TX
Sponsor: Crossignal Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06598007

Phase1, Phase2, Recruiting